Individual immunotherapy is used in the treatment of autoimmune diseases of various forms, with a focus on atopic diseases such as neurodermatitis, psoriasis, bronchial asthma, rheumatism and inflammatory bowel diseases.
The cause of these diseases is in most cases an imbalance in the immune balance. The restoration of the balance and the associated alleviation of the symptoms of the disease up to freedom from symptoms are the goal of treatment with Individual Immunotherapy.
The exogenous and endogenous factors that lead to an autoimmune disease are as diverse as the patient's own clinical picture. The Individual Immunotherapy uses the patient-specific immune response to the individual immune system. A personalized immunotherapeutic is produced from the patient's own material (patient's own blood, blood plasma or urine), which represents the entire complexity of the personal immune response.
Individual immunotherapy is an immunomodulating therapy. The body's own proteins and protein fractions are slightly modified and returned to the body. There they are recognized as foreign and the formation of antibodies against these slightly modified endogenous proteins is stimulated. The previously excessive reaction can be mitigated, the clinical picture can improve or be stopped.
In addition to the external effects, Individual Immunotherapy also shows a change in measurable physiological parameters that are detectable during the inflammatory reaction in atopics. The frequently present imbalance of the TH1-TH2 immune balance can be regulated.
Considering the fact that more and more people suffer from atopic diseases, Individual Immunotherapy as a gentle treatment method represents a real chance and hope for those affected.
Depending on the age, diagnosis and severity of the disease, the optimal form of therapy is selected in collaboration between the therapist and the patient.
As individual as the respective composition of the patient's own medicine, so individual can be the dosage form and the dosage of the medicines.
Individual immunotherapeutics based on blood/blood plasma are offered as drop preparations or as combination preparations in the form of drops and syringes for subcutaneous (under the skin) injection. The number and dosage of applications vary individually and depend on the severity of the disease and the age of the patient.
By slowly increasing the dosage in strength and number of drops or injection volume, the gradual adaptation of the body to the drug takes place and it can thus develop its immunomodulatory properties in a well-tolerated manner.
All preparations can also be provided as an inhalation. Application in this form is usually in addition to the actual therapy in the form of injections and/or drops.